Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?

Company Overview - Allogene Therapeutics (ALLO) is a notable stock within the Medical sector, which comprises 932 companies and ranks 7 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - Year-to-date, Allogene Therapeutics has achieved a return of approximately 8.8%, outperforming the average gain of 7.8% for Medical stocks [4] - However, within its specific industry, Medical - Biomedical and Genetics, which includes 453 stocks, ALLO is slightly underperforming, as the average return for this group is 19.1% [6] Analyst Sentiment - The Zacks Consensus Estimate for Allogene Therapeutics' full-year earnings has increased by 3% over the past quarter, reflecting improved analyst sentiment [3] - Comparatively, another stock in the Medical sector, AN2 Therapeutics, Inc. (ANTX), has shown a year-to-date return of 15.8% and a 5.2% increase in its consensus EPS estimate over the last three months, also holding a Zacks Rank of 2 (Buy) [4][5] Industry Context - The Medical - Biomedical and Genetics industry ranks 103 in the Zacks Industry Rank, indicating a competitive landscape [6] - Investors are encouraged to monitor both Allogene Therapeutics and AN2 Therapeutics, Inc. for their ongoing performance in the sector [7]